在耐火性多发性髓瘤中,卡菲尔佐米布诱导的危及生命的肺损伤
Rola Ghasoub1, Maria Benkhadra1, Nancy Kassem1
1Clinical Pharmacy Department, Hamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar.
概括
严重的肺损伤可能发生在多发性骨髓瘤患者接受治疗的 carfilzomib,一个蛋白酶体抑制剂. 这一案例突出了可能导致危及生命的肺毒性,强调了对卡菲尔佐米布不良事件的警监测的必要性.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡菲尔佐米布 (Carfilzomib) 是一种蛋白酶体抑制剂,用于复发性/耐药性多发性髓瘤.
- 虽然一般耐受性很好,但卡菲尔佐米布可能会引起呼吸系统的副作用.
- 严重的肺毒性是与卡菲尔佐米布治疗相关的罕见但严重的不良事件.
相关概念视频
Acute Respiratory Failure-III
227
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
227
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


